Review

• Drug resistance and combating drug resistance in cancer
• Emerging targets in cancer drug resistance
• Mechanism of resistance to immune checkpoint inhibitors
• Molecular mechanisms of enzalutamide resistance in prostate cancer
• New insights into acquired endocrine resistance of breast cancer
• Overcome cancer drug resistance by targeting epigenetic modifications of centrosome
• Pharmacogenetic and pharmacogenomic discovery strategies
• Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
• Pharmacogenetics of thiopurines
• Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients
• Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
• The epigenome in pediatric acute lymphoblastic leukemia:drug resistance and therapeutic opportunities
• The role of histone lysine demethylases in cancer cells' resistance to tyrosine kinase inhibitors

Perspective

• Perspective:plasticity,the enemy of the good

Opinion

• Glutaminase inhibition in renal cell carcinoma therapy

Commentary

• Resistance to ERK1/2 pathway inhibitors; sweet spots,fitness deficits and drug addiction

• Daunorubicin can eliminate iPS-derived cancer stem cells via lCAD/CAD-independent DNA fragmentation